November/December 2024

COVER

2025 COMPANY PROFILES & CAPABILITIES

For each participating company, this section presents a detailed summary highlighting their core technologies, capabilities, technologies, and services.

FEATURES

2025 COMPANY PROFILES & CAPABILITIES

For each participating company, this section presents a detailed summary highlighting their core technologies, capabilities, technologies, and services.

FORMULATION FORUM - Nanoparticle Technology for Nose-to-Brain Drug Delivery

Jim Huang, PhD, and Shaukat Ali, PhD, say as we continue our investigation of innovative delivery routes for drug molecules besides the parenteral and oral routes, the IN route remains the future method for drug delivery to the brain.

MULTILAYER PLASTIC VIALS - OXYCAPT™: Contributing to Stability of Cell & Gene Therapy Products

Shota Arakawa, MSc, and Tomohiro Suzuki believe OXYCAPT offers a multitude of benefits to the rapidly growing field of cell and gene therapy products.

DRUG DEVELOPMENT - Targeting the CD40L Pathway to Improve Immunosuppression Therapy & Help Organ Transplants Last Longer

David-Alexandre C. Gros, MD, explains how researchers are targeting strategies in immunosuppression that can help donated kidneys remain healthy and viable for much longer post-transplant, thus alleviating the need for repeat transplants and making more organs available for first-time transplant recipients.

MODIFIED RELEASE - Getting the Right Formula: Using Modified-Release Formulations to Address Complex Challenges in Drug Development

Vanessa Zann, PhD, presents the opportunities and challenges when transitioning from an IR to MR formulation, and reviews the therapeutic benefits and challenges associated with MR formulations, GI physiology environments and API physicochemical properties, technology choices, and how drug developers can achieve translation success.

DIGITIALIZATION PLATFORM - Breaking Down Communication Barriers in Pharma Manufacturing

Andreas Eschbach says a people-centered approach to digitizing manufacturing operations helps ensure the success of any digitalization initiative. But in pharmaceutical manufacturing, having insights into each area of operation is critical to production quality and compliance.

EXECUTVE INTERVIEW - Aptar: Advancing Patient-Centric Drug Delivery & Digital Health Solutions

Gael Touya, President of Aptar Pharma, and Sai Shankar, President, M&A, Strategy, BD, Marketing, Drug Services, Aptar Pharma, discuss the burgeoning potential in the future of pharma and digital health, how the company is a strategic partner to key players in these spaces, and the investments Aptar is making to support the growing demand.

EXECUTIVE INTERVIEW - Lonza: Utilizing Analytical Tools & Predictive Models to De-Risk Drug Development

Drug Development & Delivery recently interviewed Josh Marsh, Bioavailability Enhancement and PBPK Lead Scientist at Lonza, to discuss the benefits of predictive tools and Lonza’s approach.